eletriptan / Generic mfg. - LARVOL DELTA

Ischemic Colitis Reporting Across the Triptan Class: A Cross-Database Analysis With FDA Label Review (ACG 2026) - " We queried the FDA Adverse Event Reporting System (FAERS) and WHO VigiBase on 5/1/2026 for IC reports associated with sumatriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, eletriptan, and frovatriptan... Sumatriptan had the highest absolute IC case volume (FAERS: 87 cases; VigiBase: 114 cases) consistent with its dominant overall reporting volume. Rizatriptan was the only agent with significantly elevated IC reporting proportions in both FAERS (1.76% vs 0.79%, p=0.0007) and VigiBase (0.55% vs 0.31%, p=0.009). Frovatriptan was elevated in FAERS only (4.48% vs 0.85%, p=0.020)."

Review • Cardiovascular • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Migraine

Drugs for acute treatment of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

The Remote Electrical Neuromodulation (REN) wearable reduces medication use for the treatment of chronic pain in migraine patients (PAINWeek 2026) - "Medication types included three categories that were presented to patients using commercial drug names: (1) over-the-counter (OTC; e.g. Advil, Excedrin, Tylenol), (2) first-line prescribed medications including oral triptans (e.g. Imitrex, Maxalt, Relpax) and oral medication for nausea (e.g. Zofran, Reglan, Compazine), (3) second-line prescribed medications including nasal/injectable triptans (e.g. Tosymara, Onzetra, Zembrace, Zoming) and branded new generation medications (Reyvow, Nurtec, and Ubrelvy). Data from 31,516 migraine patients who conducted 148,705 REN treatments were analyzed. Treatment-level analysis showed that 71.1% of the treatments were performed without the use of any prescribed medications (50.6% REN alone, 14.4% REN + OTC meds), while 28.9% were conducted in conjunction with first- or second-line prescribed medications. A patient-level analysis looked at a subset of 2,653 patients who performed at least 10 REN treatments each, in which they reported..."

Clinical • CNS Disorders • Migraine • Pain

Comparison table: Triptans. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Eletriptan-Associated Coronary Vasospasm in a Heart Transplant Recipient. (PubMed, JACC Case Rep) - "Drug-induced coronary vasospasm should be considered in heart transplant recipients with acute coronary syndrome after exposure to vasoconstrictive medications. Recognition of reversible vasospasm may prevent unnecessary coronary intervention and inappropriate escalation of vasculopathy management."

Journal • Acute Coronary Syndrome • Cardiovascular • CNS Disorders • Migraine • Pain • Transplantation

Chronic Migraine Resistance: A Case Report Highlights an Overlooked Factors in Family Medicine Clinics. (PubMed, Healthcare (Basel)) - "Case presentation: A woman in her 40s with a 10-year history of migraine developed chronic daily headaches after years of near-daily eletriptan use... This case demonstrates that unrecognized medication overuse, combined with stress and unrestricted access to triptans, can mimic treatment-resistant migraine. Chronic migraine can be managed and prevented through early screening for MOH, structured patient education, multidisciplinary management approaches, and strict regulation of OTC triptan dispensing."

Journal • CNS Disorders • Migraine • Pain

Eletriptan HBr Loaded Solid Lipid Nanoparticle Integrated Microneedles: A Targeted and Minimally Invasive Approach for Migraine Management. (PubMed, J Drug Target) - "FTIR and XRD analyses confirmed drug excipient compatibility and formulation stability. In vivo evaluation in Wistar rats revealed significant antinociceptive, anxiolytic, and anti-photophobic effects (p ≤ 0.027), and reduced neurogenic inflammation confirming the enhanced brain delivery and bioavailability of EHBr."

Journal • CNS Disorders • Inflammation • Migraine • Pain • CYP3A4

The impact of ubrogepant on the use of other migraine acute treatments, opioid discontinuation, and healthcare utilization: Results from a pre-post opioid subcohort analysis (AHS 2026) - "Acute medications other than ubrogepant included acetaminophen, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, dihydroergotamine, ergotamine, amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital, talbutal, barbital, codeine, hydrocodone, meperidine, morphine, oxycodone, propoxyphene, tramadol, aspirin, bromfenac, celecoxib, diclofenac, diflunisal, esomeprazole, etodolac, famotidine, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, lasmiditan, Zavegepant, and Rimegepant (<15 pills). Opioid use included acetaminophen/tramadol, oxymorphone, levorphanol, buprenorphine/naloxone, meperidine, morphine, oxycodone, codeine, methadone, oxycodone, hydromorphone, butorphanol, and tapentadol... In patients with a history of opioid use,..."

HEOR • CNS Disorders • Migraine • Pain

Spoken language and limited english proficiency as a barrier to care for the acute treatment of migraine: Results from a cross-institutional electronic health record (AHS 2026) - "Patients who spoke 24/28 (86%) of the non-English languages had an increased OR for receiving sumatriptan and they broadly had lower ORs for rizatriptan, eletriptan, zolmitriptan, naratriptan, rimegepant, and ubrogepant. Spoken language is an underexplored barrier to care in headache medicine. Our study demonstrates that patients who do not speak English often have lower rates of being prescribed acute medications for migraine overall and particularly for non-sumatriptan acute medications. Limited English proficiency remains an important social determinant of health, including accessing migraine medications."

Clinical • CNS Disorders • Migraine • Pain

The Efficacy and Safety of Triptans in Pediatric Migraine: A Systematic Review, Pairwise and Network Meta-Analysis (PAS 2026) - "Network meta-analysis ranked eletriptan 40 mg best for 24-hour sustained pain relief (SUCRA = 0.98), sumatriptan 50 mg for 30-minute (SUCRA = 0.84), and zolmitriptan 2.5 mg for both 1-hour (SUCRA = 0.83) and 2-hour headache relief (SUCRA = 0.82). Fifteen RCTs, comprising 5903 patients, matched the inclusion criteria. Triptans significantly improved 24-hour sustained pain relief (RR = 1.36, 95% CI 1.04-1.79, P = 0.034), 30-minute (RR = 1.4, 95% CI 1.07-1.85, P = 0.027), and 2-hour headache relief (RR = 1.32, 95% CI 1.05-1.66, P = 0.02) compared with placebo. Additionally, triptans significantly reduced the need to use additional painkillers in the first two hours (RR=0.67, p=0.015)."

Retrospective data • Review • CNS Disorders • Depression • Migraine • Pain • Pediatrics

Novel Application of UHPLC-MS, HRMS, and 2D-NMR for Structural Elucidation of Eletriptan Hydrobromide and Its Novel Degradation Products. (PubMed, Biomed Chromatogr) - "Three new degradation products were identified and isolated from oxidative degradation and a new degradation product isolated from the acid degradation, providing the first documented structural characterization of all four degradation products. Furthermore, we develop a UPLC MS method having 8-min runtime and good peak shape and resolution by using Acquity BEH C18 column (100 × 2.1 mm, 1.7 μm) column."

Journal

Middle meningeal artery lidocaine infusion for refractory migraine: First case report in Portugal (EHF-EHC 2025) - "Various pharmacologic classes were tried without benefit: antihypertensives and calcium channel blockers (propranolol, candesartan, flunarizine), antiepileptics (valproic acid, topiramate, oxcarbazepine), antidepressants (amitriptyline, nortriptyline, venlafaxine, fluvoxamine, sertraline, clomipramine), other preventives (prednisolone, oxitriptan, melatonin), cycles of botulinum toxin (PREEMPT protocol), monoclonal antibodies (galcanezumab, fremanezumab, erenumab), and atogepant. At the time of the procedure, the patient was on eptinezumab 100 mg and botulinum toxin every three months but continued to have daily headaches, with severe intensity and reliance on eletriptan for acute relief... MMA lidocaine infusion has been described in few cases, and this is, to our knowledge, the first reported in Portugal. It constitutes an invasive therapeutic approach that should be considered only as a rescue option for carefully selected patients with severely refractory migraine...."

Case report • Clinical • Anorexia • CNS Disorders • Migraine • Pain

Real-world comparative analysis of migraine attack abortive therapies: Insights from over 59 million patient records in the Migrebot e-Diary (EHF-EHC 2025) - "In this very large, fully naturalistic dataset, eletriptan was associated with the greatest user-reported relief among the medications studied. While self-selection, reporting bias, attack heterogeneity, and the absence of randomization limit causal inference, e-diaries can complement clinical trials by providing rapid, global, real-world signals at scale Fig. 1 Fig."

Clinical • Real-world • Real-world evidence • CNS Disorders • Migraine • Pain

Hyperprolactinemia and migraine-like headache: A case report and literature review (EHF-EHC 2025) - "She was treated with bromocriptine for three months, achieving complete headache resolution...Repeat MRI showed a pituitary microadenoma, and cabergoline was reinitiated, with significant headache improvement...Eletriptan was prescribed for acute attacks... This case supports the role of PRL in migraine-like headaches via neuromodulatory effects, independent of tumor mass. PRL receptors in trigeminal pathways suggest a sensitization mechanism. Dopamine agonists may relieve symptoms, even without tumor shrinkage, indicating a hormonal component."

Case report • Clinical • Review • CNS Disorders • Endocrine Disorders • Gynecology • Migraine • Pain

Classifying Effluxable Versus Non-Effluxable Compounds Using a Permeability Threshold Based on Fundamental Energy Constraints. (PubMed, Pharmaceutics) - "Concentration-dependent measurements for Amprenavir, Eletriptan, Loperamide, and Quinidine-chosen because these borderline compounds exhibited the highest Pm×Cext while still being actively effluxed-enabled the most accurate determination of the threshold. In contrast, more than 60% of the compounds analyzed without significant ER values (123 compounds) fell above the threshold, in strong agreement with our theory of an energy limitation to active transport. This permeability threshold thus provides a simple and broadly applicable criterion to identify compounds for which active efflux is energetically not feasible and may serve as a practical tool for early drug discovery and optimization, pending further validation in practical applications."

Journal • ABCB1

Response to intravenous dihydroergotamine (DHE) for the treatment of refractory chronic migraine in adolescent patients (IHC 2025) - "Pre-infusion ondansetron 150 mcg/kg and prochlorperazine 5 mg/kg were administered PRN...For management, 54% (14/26) used sumatriptan,19% (5/26) used rizatriptan, 23% (6/26) used zolmitriptan, and 4% (1/26) used eletriptan. Preventively, 31% (8/26) had used propranolol, 23% (6/26) topiramate, 23% (6/26) amitriptyline, and 23% (6/26) pizotifen...This may include infusion slowing and increasing anti-emetic breadth and doses. Larger longer-term follow up studies are needed."

Clinical • CNS Disorders • Migraine

Profile of triptan use and efficacy in migraine patients treated with Anti-CGRP monoclonal antibodies (EAN 2025) - "Fremanezumab was the prevailing mAb (66,28%)...Before starting mAbs, 69 patients (80.29%) used triptans, mainly zolmitriptan (36.23%) and eletriptan (34.78%)... As previously suggested in other studies, preliminary findings indicate that anti-CGRP mAbs may reduce the need for triptans in migraine management. Despite anecdotal reports of triptan efficacy loss, so far our data did not support this. Further studies are needed to explore this interaction."

Clinical • CNS Disorders • Migraine • Pain

eSpine: Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury (clinicaltrials.gov) - P1/2 | N=28 | Recruiting | Sponsor: Technophage, SA | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2026 ➔ Jun 2027 | Initiation date: Jan 2025 ➔ Aug 2025 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • CNS Disorders • Orthopedics

Drug screening of wildtype voltage-gated sodium channels Nav1.3, Nav1.5 and Nav1.6: a systematic analysis of over 350 substances (NeuPSIG 2025) - "We conducted a dose response screening with 25 agents like Sertraline, Memantine and Eletriptan on Nav 1.5 in a subsequent study, to reveal potential mechanisms of cardiac side effects. The identification of unanticipated interactions between FDA-approved drugs and voltage-gated sodium channels highlights the significance of off-target effects that have long been underexplored. The identification of unanticipated interactions between FDA-approved drugs and voltage-gated sodium channels highlights the significance of off-target effects that have long been underexplored. These interactions could provide valuable insights into drug-induced side effects or reveal novel mechanisms that may influence pain, safety, and therapeutic efficacy. By uncovering these off-target effects, we can refine our understanding of drug pharmacology, improve the safety profiles of existing drugs, and potentially point towards new avenues for pain management."

CNS Disorders • NAV1

The impact of headache specialist density and the introduction of gepants and lasmitidan on prescriptions for acute migraine treatments: a regression and interrupted time series analysis. (PubMed, Front Neurol) - "In our interrupted time-series analysis, the introduction of the gepants and lasmiditan was linked to decreases in triptan utilization, except for eletriptan which remained stable, and rizatriptan which rose at a slower rate...Our study suggests increased headache provider availability is associated with more prescriptions for naratriptan, eletriptan, and almotriptan. Additionally, the introduction of the gepants and lasmiditan broadly decreased the utilization of triptans. Critically, there was a strong association between a pharmaceutical company's, Pfizer, payments to physicians and utilization of their medication, rimegepant."

Journal • CNS Disorders • Migraine • Pain

Curvilinear regression analysis and ranking of migraine treatment drugs using degree-based topological indices and the WASPAS method. (PubMed, Comput Biol Med) - "In this study, we calculate several degree-based topological indices for a range of migraine treatment medications, including aspirin, caffeine, eletriptan, ergotamine, sumatriptan, rizatriptan, verapamil, diclofenac, frovatriptan, and droperidol. This research emphasizes the application of curvilinear regression techniques and performs extensive testing using these models to enhance the understanding of drug properties. The Weighted Aggregated Sum Product Assessment (WASPAS) method is applied to evaluate and rank these drugs based on various topological indices attributes, integrating both the weighted sum model and the weighted product model to provide a comprehensive assessment."

Journal • CNS Disorders • Migraine • Pain

A Pilot Study on the Drug Price Revision Strategy in Japan: A Comparison Among Fiscal Years 2018, 2020, and 2022. (PubMed, Hosp Pharm) - "In FY2020, sumatriptan and eletriptan were cost-effective, and rizatriptan was extended-dominated; nevertheless, the other triptans were dominated by sumatriptan. In FY2022, naratriptan and eletriptan were cost-effective; however, the other triptans were dominated by naratriptan...The variations could be problematic because in Japan, formulary management of triptans, for example, those for migraine, may face revaluation every other year. Discussions regarding this issue will be further explored in the future."

Journal • CNS Disorders • Migraine • Pain

eSpine: Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury (clinicaltrials.gov) - P1/2 | N=28 | Not yet recruiting | Sponsor: Technophage, SA

New P1/2 trial • CNS Disorders • Orthopedics

Regional distribution of unbound eletriptan and sumatriptan in the CNS and PNS in rats: implications for a potential central action. (PubMed, J Headache Pain) - "This study suggests that despite low BBB transport, both eletriptan and sumatriptan achieve unbound concentrations sufficient to stimulate 5-HT1B, 5-HT1D, and 5-HT1F receptors not only in the trigeminal ganglion, but also in the CNS. Further research is needed to determine whether central mechanisms contribute to triptan's antimigraine effect and/or side effects."

Journal • Preclinical • CNS Disorders • Migraine • Pain

Advancing migraine therapy with novel mucoadhesive eletriptan formulations (Neuroscience 2024) - "Additionally, analytical methods for eletriptan estimation using UV-visible spectroscopy and HPLC with UV detection were developed and validated. Results demonstrated the potential of mucoadhesive formulations to enhance drug absorption and efficacy, offering a promising avenue for improving migraine therapy outcomes."

Late-breaking abstract • CNS Disorders • Migraine • Pain